Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study.

Laasik M, Kemppainen J, Auranen A, Hietanen S, Grénman S, Seppänen M, Hynninen J.

Cancer Imaging. 2019 May 29;19(1):27. doi: 10.1186/s40644-019-0215-7.

2.

Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer.

Hynninen J, Laasik M, Vallius T, Kemppainen J, Grönroos S, Virtanen J, Casado J, Hautaniemi S, Grenman S, Seppänen M, Auranen A.

Clin Oncol (R Coll Radiol). 2018 Aug;30(8):507-514. doi: 10.1016/j.clon.2018.04.007. Epub 2018 May 9.

PMID:
29753662
3.

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.

Huvila J, Laajala TD, Edqvist PH, Mardinoglu A, Talve L, Pontén F, Grénman S, Carpén O, Aittokallio T, Auranen A.

Gynecol Oncol. 2018 Apr;149(1):173-180. doi: 10.1016/j.ygyno.2018.02.016. Epub 2018 Mar 2.

PMID:
29486992
4.

18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

Vallius T, Hynninen J, Kemppainen J, Alves V, Auranen K, Matomäki J, Oksa S, Virtanen J, Grénman S, Auranen A, Seppänen M.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1224-1232. doi: 10.1007/s00259-018-3961-z. Epub 2018 Feb 23.

PMID:
29476227
5.

The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.

Kemiläinen H, Huhtinen K, Auranen A, Carpén O, Strauss L, Poutanen M.

Oncology. 2018;94(4):233-242. doi: 10.1159/000485624. Epub 2018 Jan 12.

PMID:
29324448
6.

Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.

Vallius T, Hynninen J, Auranen A, Matomäki J, Oksa S, Roering P, Grènman S.

Tumour Biol. 2017 Feb;39(2):1010428317691189. doi: 10.1177/1010428317691189.

PMID:
28218038
7.

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G.

Br J Cancer. 2017 Feb 14;116(4):455-463. doi: 10.1038/bjc.2016.435. Epub 2017 Jan 24.

8.

A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.

Gidwani K, Huhtinen K, Kekki H, van Vliet S, Hynninen J, Koivuviita N, Perheentupa A, Poutanen M, Auranen A, Grenman S, Lamminmäki U, Carpen O, van Kooyk Y, Pettersson K.

Clin Chem. 2016 Oct;62(10):1390-400. doi: 10.1373/clinchem.2016.257691. Epub 2016 Aug 18.

9.

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.

Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O.

PLoS One. 2016 Mar 16;11(3):e0151590. doi: 10.1371/journal.pone.0151590. eCollection 2016.

10.

18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J.

Gynecol Oncol. 2016 Jan;140(1):29-35. doi: 10.1016/j.ygyno.2015.10.018. Epub 2015 Oct 26.

PMID:
26515076
11.

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomäki V, Lindell R, Hynninen J, Auranen A, Grénman S, Lehtonen R, Carpén O, Hautaniemi S.

Cancer Res. 2015 Aug 1;75(15):2987-98. doi: 10.1158/0008-5472.CAN-14-3242. Epub 2015 Jun 29.

12.

Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.

Edqvist PH, Huvila J, Forsström B, Talve L, Carpén O, Salvesen HB, Krakstad C, Grénman S, Johannesson H, Ljungqvist O, Uhlén M, Pontén F, Auranen A.

Gynecol Oncol. 2015 Jun;137(3):529-37. doi: 10.1016/j.ygyno.2015.03.055. Epub 2015 Apr 7.

PMID:
25858696
13.

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.

Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, Virtanen J, Grénman S.

Tumour Biol. 2014 Dec;35(12):12389-95. doi: 10.1007/s13277-014-2553-1. Epub 2014 Sep 5.

PMID:
25190018
14.

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomäki J, Oksa S, Carpén O, Grénman S, Seppänen M, Auranen A.

Gynecol Oncol. 2013 Nov;131(2):389-94. doi: 10.1016/j.ygyno.2013.08.023. Epub 2013 Aug 29.

PMID:
23994535
15.

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.

Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A.

Gynecol Oncol. 2013 Sep;130(3):463-9. doi: 10.1016/j.ygyno.2013.06.015. Epub 2013 Jun 15.

PMID:
23777659
16.

[Mesenterial fibrosis--could it be desmoidi?].

Auranen A, Kallajoki M, Lavonius M, Lindholm P.

Duodecim. 2012;128(24):2562-8. Review. Finnish.

PMID:
23393930
17.

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A.

Gynecol Oncol. 2013 Feb;128(2):229-32. doi: 10.1016/j.ygyno.2012.11.007. Epub 2012 Nov 9.

PMID:
23142076
18.

[Update on current care guidelines: ovarian cancer].

Leminen A, Auranen A, Bützow R, Hietanen S, Komulainen M, Kuoppala T, Mäenpää J, Puistola U, Vuento M, Vuorela P, Yliskoski M.

Duodecim. 2012;128(12):1300-1. Review. Finnish.

PMID:
22822606
19.

FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.

Hynninen J, Auranen A, Carpén O, Dean K, Seppänen M, Kemppainen J, Lavonius M, Lisinen I, Virtanen J, Grénman S.

Gynecol Oncol. 2012 Jul;126(1):64-8. doi: 10.1016/j.ygyno.2012.04.023. Epub 2012 Apr 24.

PMID:
22542580
20.

Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer.

Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppänen M, Grénman S.

Int J Gynecol Cancer. 2011 Dec;21(9):1573-8. doi: 10.1097/IGC.0b013e3182225509.

PMID:
21811175
21.

Subspecialist training in surgical gynecologic oncology in the Nordic countries.

Antonsen SL, Avall-Lundqvist E, Salvesen HB, Auranen A, Salvarsdottir A, Høgdall C; Nordic Society of Gynaecological Oncology.

Acta Obstet Gynecol Scand. 2011 Aug;90(8):917-20. doi: 10.1111/j.1600-0412.2011.01179.x. Epub 2011 Jun 16.

PMID:
21564027
22.

A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families.

Auranen A, Joutsiniemi T.

Acta Obstet Gynecol Scand. 2011 May;90(5):437-44. doi: 10.1111/j.1600-0412.2011.01091.x. Epub 2011 Mar 16. Review.

PMID:
21306348
23.

Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors.

Huvila J, Brandt A, Rojas CR, Pasanen S, Talve L, Hirsimäki P, Fey V, Kytömäki L, Saukko P, Carpén O, Soini JT, Grénman S, Auranen A.

Int J Gynecol Cancer. 2009 Oct;19(7):1226-31. doi: 10.1111/IGC.0b013e3181b33be0.

PMID:
19823059
24.

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.

Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A.

Br J Cancer. 2009 Apr 21;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. Epub 2009 Mar 31.

25.

Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer.

Auranen A, Grénman S.

Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6. doi: 10.1111/j.1525-1438.2007.01105.x.

PMID:
18336400
26.

Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature.

Auranen A, Sundström J, Ijäs J, Grénman S.

Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1011-8. Epub 2007 Mar 21. Review.

PMID:
17374124
27.

Gynekologisten syöpien leikkaushoidon keskittäminen Suomessa.

Grénman S, Auranen A.

Duodecim. 2006;122(19):2367-8. Finnish. No abstract available.

PMID:
17115548
28.

Hormonal treatments and epithelial ovarian cancer risk.

Auranen A, Hietanen S, Salmi T, Grénman S.

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):692-700. Review.

29.

Polymorphisms in DNA repair genes and epithelial ovarian cancer risk.

Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, Hogdall E, Hogdall C, Stratton J, Whittemore AS, Easton DF, Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD.

Int J Cancer. 2005 Nov 20;117(4):611-8.

30.

[Is estrogen replacement therapy increasing or decreasing the risk of cancer?].

Auranen A, Grénman S, Anttila L, Salmi T.

Duodecim. 2003;119(22):2199-206. Review. Finnish. No abstract available.

PMID:
14702809
31.

Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk.

Kuschel B, Auranen A, Gregory CS, Day NE, Easton DF, Ponder BA, Dunning AM, Pharoah PD.

Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):809-12.

32.

BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.

Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, Green A, Healey CS, Redman K, Dunning AM, Pharoah PD, Easton DF, Ponder BA, Chenevix-Trench G, Novik KL.

Int J Cancer. 2003 Jan 20;103(3):427-30. Erratum in: Int J Cancer. 2003 May 10;104(6):799.

33.

Variants in DNA double-strand break repair genes and breast cancer susceptibility.

Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD, Dunning A.

Hum Mol Genet. 2002 Jun 1;11(12):1399-407.

PMID:
12023982
34.

BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.

Sarantaus L, Auranen A, Nevanlinna H.

Int J Oncol. 2001 Apr;18(4):831-5.

PMID:
11251181
35.

PROGNOSTICATION OF BREAST CANCER BY MULTIVARIATE METHODS.

Collan Y, Kuopio T, Auranen A, Linna M.

Adv Clin Path. 1997 Oct;1(4):269-273.

PMID:
10352489
36.

Segregation analysis of epithelial ovarian cancer in Finland.

Auranen A, Iselius L.

Br J Cancer. 1998 May;77(9):1537-41.

37.

A missense mutation in the BRCA2 gene in three siblings with ovarian cancer.

Roth S, Kristo P, Auranen A, Shayehgi M, Seal S, Collins N, Barfoot R, Rahman N, Klemi PJ, Grénman S, Sarantaus L, Nevanlinna H, Butzow R, Ashworth A, Stratton MR, Aaltonen LA.

Br J Cancer. 1998 Apr;77(8):1199-202.

38.
39.

[Cancer incidence in the first-degree relatives of ovarian cancer patients].

Auranen A, Pukkala E, Mäkinen J, Sankila R, Grénman S, Salmi T.

Duodecim. 1997;113(1):46-50. Finnish. No abstract available.

PMID:
11370054
40.

Borderline ovarian tumors in Finland: epidemiology and familial occurrence.

Auranen A, Grénman S, Mäkinen J, Pukkala E, Sankila R, Salmi T.

Am J Epidemiol. 1996 Sep 15;144(6):548-53.

PMID:
8797514
41.

Cancer incidence in the first-degree relatives of ovarian cancer patients.

Auranen A, Pukkala E, Mäkinen J, Sankila R, Grénman S, Salmi T.

Br J Cancer. 1996 Jul;74(2):280-4.

42.

Subrenal capsule assay in human breast cancer. Response to cytostatic drug combinations and correlation with receptor status.

Aho AJ, Mäenpää JU, Kangas L, Söderström KO, Auranen AA, Linna M.

Eur J Cancer Clin Oncol. 1985 Oct;21(10):1133-40.

PMID:
4076280
43.

[Inoperable pheochromocytoma].

Lehtonen A, Auranen A.

Duodecim. 1981;97(23-24):1953-5. Finnish. No abstract available.

PMID:
7344933
44.

[Primary treatment of breast cancer].

Auranen A, Rissanen P.

Duodecim. 1979;95(12):754-9. Finnish. No abstract available.

PMID:
520196
45.

Primary lymphosarcoma of the thyroid gland. Report of a case confirmed by electron microscopy.

Anttinen J, Auranen A, Nordman E, Viikari J.

Ann Chir Gynaecol Suppl. 1977;66(5):227-9. No abstract available.

PMID:
579570
46.

The rate of drug biotransformation reactions and cellular viability in the livers of patients with biliary diseases.

Hietanen E, Auranen A, Savvakis Ch.

Acta Hepatogastroenterol (Stuttg). 1975 Jun;22(3):170-5.

PMID:
1220509
47.

The effect of a distant reparative process on rat liver function.

Ahonen J, Auranen A, Hvitfelt KJ.

Eur Surg Res. 1973;5(4):259-67. No abstract available.

PMID:
4359753
48.

Effect of biliary tract obstruction on liver microsomes in the rat.

Auranen A, Ahonen J, Hvitfelt J.

Eur Surg Res. 1973;5(3):228-32. No abstract available.

PMID:
4356070
50.

Analysis of cauda equina symptoms in patients with lumbar disc prolapse. Preoperative and follow-up clinical and cystometric studies.

Aho AJ, Auranen A, Pesonen K.

Acta Chir Scand. 1969;135(5):413-20. No abstract available.

PMID:
5354193

Supplemental Content

Loading ...
Support Center